Neuroleptics differentially modulate central dopamine d1-receptor binding

Mostrar otras versiones (1)

The effect of the classical neuroleptic, fluphenazine, on dopamine D1-receptor binding was examined in different regions of the basal ganglia. Whereas exposure to fluphenazine for 18 months reduced [125I]SCH-23982 binding to D1-receptors in the caudate putamen, nucleus accumbens and olfactory tuberc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Johnson, A.E
Otros Autores: Coirini, H., Källström, L., Gunne, L.M, Wiesel, F.A
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 1995
Materias:
sch 23388; sch 23390; sch 23982, new england nuclear, Sweden; skf 38393
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 07381caa a22012137a 4500
001 PAPER-19052
003 AR-BaUEN
005 20230518205025.0
008 190411s1995 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0028936887 
024 7 |2 cas  |a 2 dipropylamino 7 hydroxytetralin, 74938-11-7; 2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine, 67287-49-4; 2,3,4,5 tetrahydro 8 iodo 3 methyl 5 phenyl 1h 3 benzazepin 7 ol, 116780-39-3; 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate, 87134-87-0; clozapine, 5786-21-0; dopamine, 51-61-6, 62-31-7; fluphenazine, 146-56-5, 69-23-8; raclopride, 84225-95-6; Antipsychotic Agents; Dopamine Antagonists; Iodine Radioisotopes; Receptors, Dopamine D1; Sch 23982, 116780-39-3; Sch-23390, 87075-17-0 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
100 1 |a Johnson, A.E. 
245 1 0 |a Neuroleptics differentially modulate central dopamine d1-receptor binding 
260 |c 1995 
270 1 0 |m Johnson, A.E.; Department of Psychiatry, University Hospital, Uppsala University, Uppsala, S-750 17, Sweden 
506 |2 openaire  |e Política editorial 
504 |a Wiesel, F.-A., (1994) Brit J Paychiet, 184, pp. 65-70 
504 |a Angulo, J.A., McEwen, B.S., (1994) Brain Res Rav, 19, pp. 1-28 
504 |a Gerfen, C.R., (1992) Annu Rev Naurosci, 15, pp. 285-320 
504 |a Altar, C.A., Marian, M.R., (1987) J Neurosci, 7, pp. 213-222 
504 |a Dawson, T.M., Barone, P., (1988) Sidhu a at Al. Neuroscience, 29, pp. 83-100 
504 |a Johnson, A.E., Coirini, H., Kallstrdm, L., (1994) Neuroreport, 5, pp. 1836-1838 
504 |a Albin, R.L., Young, A.B., Penney, J.B., (1989) Trends Neurosci, 12, pp. 366-375 
504 |a Delong, M.R., (1990) Trends Neurosci, 13, pp. 281-285 
504 |a Mercugliano, M., Sailer, C.F., Salama, A.I., (1992) Neuropsychopharmacologia, 6, pp. 179-187 
504 |a Johnson, A.E., Liminga, U., Liddn, A., (1994) Neuroscience, 63, pp. 1003-1020 
504 |a Marder, S.R., Hubbard, J.W., Van Putten, T., (1989) Psychopharmacology, 98, pp. 433-439 
504 |a Paxinos, G., Watson, C., (1986) The Rat Brain in Stereotaxic Coordinates, , New York: Academic Press 
504 |a Bjdrklund, A., Undvall, O., Dopamine-containing systems in the CNS (1984) Handbook of Chemical Neuroanatomy, pp. 55-122. , Bjdrklund A and Hokfelt T, eds., Amsterdam: Elsevier 
504 |a Hokfelt, T., Mdrtensson, R., Bjorklund, A., Distributional maps of tyrosine-hydroxy-lase-immunoreactive neurons in the rat brain (1984) Handbook of Chemical Neuroanatomy, pp. 277-379. , Bjdrklund A and Hokfelt T, eds., Amsterdam: Elsevier 
504 |a Creese, I., Chen, A., (1985) Eur J Pharmacol, 109, pp. 127-128 
504 |a Duncan, G.E., Criswell, H.E., McCown, T.J., (1987) J Pharmacol Exp Ther, 243, pp. 1027-1034 
504 |a Grebb, G.A., Ehrlich, M., Greengard, P., (1990) J Neurochem, 55, pp. 204-207 
504 |a Seaman, P., Grigoriadis, D., (1987) Neurochem Int, 10, pp. 1-25 
504 |a Besson, M.J., Graybiel, A.M., Nastuck, M.A., (1988) Neuroscience, 26, pp. 101-119 
504 |a Kawaguchi, Y., Wilson, C.J., Emson, P.C., (1990) J Neurosci, 10, pp. 3421-3438 
504 |a Al, L., Hersch, S.M., Rye, D.B., (1993) Proc Natl Acad Sci USA, 90, pp. 8861-8865 
504 |a Gerfen, C.R., Engber, T.M., Mahan, L.C., (1990) Science, 250, pp. 1429-1432 
504 |a Ouimet, C.C., Miller, P.E., Hammings, H.C., Jr., (1984) J Neurosci, 4, pp. 111-124 
504 |a Anderson, K.D., Reiner, A., (1991) Brain Res, 568, pp. 235-243 
504 |a Harrison, M.B., Wiley, R.G., Wooten, G.F., (1990) Brain Res, 528, pp. 317-322 
520 3 |a The effect of the classical neuroleptic, fluphenazine, on dopamine D1-receptor binding was examined in different regions of the basal ganglia. Whereas exposure to fluphenazine for 18 months reduced [125I]SCH-23982 binding to D1-receptors in the caudate putamen, nucleus accumbens and olfactory tubercle, binding in the entopeduncular nucleus was enhanced after fluphenazine treatment. Competition studies indicated that the region-dependent changes in [125I]SCH-23982 binding after fluphenazine exposure were not due to differences in the affinity of fluphenazine or other dopamine ligands for D1-binding sites. These data suggest that in addition to modulating striatal function, classical neuroleptics may also alter neurotransmission in the basal ganglia by enhancing dopamine receptor binding in the entopeduncular nucleus. © Rapid Communications of Oxford Ltd.  |l eng 
593 |a Instituto de Biología y Medicina Experimental, Buenos Aires, 1428, Argentina 
593 |a Department of Psychiatry, University Hospital, Uppsala University, Uppsala, S-750 17, Sweden 
690 1 0 |a BASAL GANGLIA 
690 1 0 |a D1-RECEPTORS 
690 1 0 |a DOPAMINE 
690 1 0 |a ENTOPEDUNCULAR NUCLEUS 
690 1 0 |a ENTOPEDUNCULAR NUCLEUS 
690 1 0 |a EXTRAPYRAMIDAL MOTOR SYSTEM 
690 1 0 |a FLUPHENAZINE 
690 1 0 |a NEUROLEPTIC 
690 1 0 |a STRIATUM 
690 1 0 |a [125I]SCH-23982 
690 1 0 |a 2 DIPROPYLAMINO 7 HYDROXYTETRALIN 
690 1 0 |a 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE 
690 1 0 |a 2,3,4,5 TETRAHYDRO 8 IODO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL 
690 1 0 |a 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE 
690 1 0 |a CLOZAPINE 
690 1 0 |a DOPAMINE 
690 1 0 |a DOPAMINE 1 RECEPTOR 
690 1 0 |a FLUPHENAZINE 
690 1 0 |a NEUROLEPTIC AGENT 
690 1 0 |a RACLOPRIDE 
690 1 0 |a ANIMAL EXPERIMENT 
690 1 0 |a ANIMAL TISSUE 
690 1 0 |a ARTICLE 
690 1 0 |a BRAIN REGION 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a CORPUS STRIATUM 
690 1 0 |a ENTOPEDUNCULAR NUCLEUS 
690 1 0 |a FEMALE 
690 1 0 |a INTRAMUSCULAR DRUG ADMINISTRATION 
690 1 0 |a NONHUMAN 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a RAT 
690 1 0 |a RECEPTOR BINDING 
690 1 0 |a SUBSTANTIA NIGRA 
690 1 0 |a ANIMAL 
690 1 0 |a ANTIPSYCHOTIC AGENTS 
690 1 0 |a AUTORADIOGRAPHY 
690 1 0 |a BASAL GANGLIA 
690 1 0 |a BINDING, COMPETITIVE 
690 1 0 |a DOPAMINE ANTAGONISTS 
690 1 0 |a FEMALE 
690 1 0 |a IODINE RADIOISOTOPES 
690 1 0 |a RATS 
690 1 0 |a RATS, SPRAGUE-DAWLEY 
690 1 0 |a RECEPTORS, DOPAMINE D1 
690 1 0 |a SCH-23390 
653 0 0 |a sch 23388; sch 23390; sch 23982, new england nuclear, Sweden; skf 38393 
700 1 |a Coirini, H. 
700 1 |a Källström, L. 
700 1 |a Gunne, L.M. 
700 1 |a Wiesel, F.A. 
773 0 |d 1995  |g v. 6  |h pp. 933-936  |k n. 6  |p NeuroReport  |x 09594965  |w (AR-BaUEN)CENRE-6274  |t NeuroReport 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028936887&doi=10.1097%2f00001756-199504190-00027&partnerID=40&md5=8fad231d0acd67a50d909705adbad7a6  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1097/00001756-199504190-00027  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_09594965_v6_n6_p933_Johnson  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09594965_v6_n6_p933_Johnson  |y Registro en la Biblioteca Digital 
961 |a paper_09594965_v6_n6_p933_Johnson  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 80005 

Ejemplares similares